Skip to main
CRIS

Curis (CRIS) Stock Forecast & Price Target

Curis (CRIS) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Curis is currently showing promising results in their clinical trials for their drugs targeting primary CNS lymphoma, with a 26% ORR on an all-patients basis and a 33% ORR in evaluable patients. Their pipeline expansion to include all five NHL subtypes and their successful enrollment in the TakeAim CLL study suggest strong potential for future growth and success. Additionally, the company's deep responses and undetectable minimal residual disease when combining emavusertib with a BTK inhibitor provide further evidence of the potential of their drugs.

Bears say

Curis is facing challenges due to the low success rate of its pipeline products, as seen in the BTKi-experienced and BTKi-naïve groups where response rates are relatively low. The company's financial update also shows a lack of profitability, with a negative EPS and small cash reserves. Additionally, the expanded TakeAim CLL readout has been delayed and the company is still in its early stages of clinical trials, making it a risky investment for potential investors.

Curis (CRIS) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Curis and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Curis (CRIS) Forecast

Analysts have given Curis (CRIS) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Curis (CRIS) has a Strong Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Curis (CRIS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.